Track Biovica International AB (publ)'s EBIT ($-71M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jul 31, 2026
Trailing 12 months ending Jul 31, 2026
The latest EBIT for BIOVIC-B.ST is $-71M as of July 2026. That compares with $-82M in the prior-year period — up 12.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Biovica International AB (publ)'s historical trend and sector peers before judging valuation or financial health.
Over the past year, BIOVIC-B.ST's EBIT moved from $-82M to $-71M — a 12.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biovica International AB (publ)'s operating scale or balance-sheet position.
Against Healthcare companies, BIOVIC-B.ST currently prints $-71M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Biovica International AB (publ)'s growth, margins, and balance sheet.
A EBIT figure of $-71M for BIOVIC-B.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.
After noting BIOVIC-B.ST's EBIT ($-71M), review year-over-year change from $-82M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.